Loading clinical trials...
Loading clinical trials...
A Phase III, Single-arm Clinical Trial of Zebutinib Combined With Immunochemotherapy With Limited Course of Treatment for Newly Treated Chronic Lymphocytic Leukemia Patients Without 17p-
Conditions
Interventions
Zebutinib&BR or Zebutinib&FCR
Start Date
September 1, 2021
Primary Completion Date
September 1, 2025
Completion Date
September 1, 2025
Last Updated
July 28, 2021
NCT07277231
NCT05006716
NCT06859424
NCT05254743
NCT01804686
NCT05371808
Lead Sponsor
Nanfang Hospital, Southern Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions